Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma-Reference-Cited by-同舟云学术

Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma

Published:2010-08-05 Issue:1 Volume:151 Page:47-53
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:

Author:

Romaguera Jorge E.,Fayad Luis E.,McLaughlin Peter,Pro Barbara,Rodriguez Alma,Wang Michael,Weaver Pamela,Hartig Kimberly,Kwak Larry W.,Feldman Tatyana,Smith Judy,Ford Peggy,Goldberg Stuart,Pecora Andrew,Goy Andre

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2010.08315.x/fullpdf

Reference22 articles.

1. In vitro studies of bortezomib with daunorubicin and cytarabine: sequence of administration affects leukemia cell chemosensitivity;Attar;Blood (ASH Annual Meeting Abstracts),2004

2. The functional assessment of cancer therapy (FACT) scale: development and validation of the general measure;Cella;Journal of Clinical Oncology,1993

3. Sensitization of leukemic cells for glucocorticoids by inhibition of NFKB activation;Cloos;Blood (ASH Annual Meeting Abstracts),2004

4. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma;Fisher;Journal of Clinical Oncology,2006

5. Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan: a questionnaire-based report from the “lung injury by bortezomib” Joint Committee of the Japanese Society of Hematology and the Japanese Society of Clinical Hematology;Gotoh;International Journal of Hematology,2006

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Experience on Proteasome Inhibitors in Cancer;Precision Cancer Therapies, Volume 1 ‐ Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies;2023-03-15

2. Mantle cell lymphoma management trends and novel agents: where are we going?;Therapeutic Advances in Hematology;2022-01

3. Phase I study of escalating doses of carfilzomib with HyperCVAD in patients with newly diagnosed acute lymphoblastic leukemia;American Journal of Hematology;2021-02-26

4. Cell-type-specific sensitivity of bortezomib in the methotrexate-resistant primary central nervous system lymphoma cells;International Journal of Clinical Oncology;2019-04-16

5. Therapeutic antibodies for mantle cell lymphoma: A brand-new era ahead;Heliyon;2019-03